Interventional cardiology in a whole new light

Open menu

News & Events

FFR: Opsens completes regulatory filing in the United States and in Europe and reports on the progress on the clinical work with its products

7 October 2014

Quebec City, Quebec, October 7, 2014 – Opsens Inc. (“Opsens”) (TSX-V: OPS) is pleased to provide a report on the progress of its FFR clinical and regulatory activities. First Clinical Work on Humans – 27 Patients Successfully Diagnosed Using Opsens’ FFR Products Opsens received the authorization from Health Canada to conduct investigational testing in patients,…

Read more